Genfit S.A. GNFTF

Company Overview

Genfit S.A. is a French biopharmaceutical company focused on developing therapies and diagnostic solutions for severe chronic liver diseases and related metabolic disorders. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a concentration on conditions that have significant unmet medical needs, including acute-on-chronic liver failure (ACLF), cholangiocarcinoma, and other liver-related diseases. Genfit has historically been associated with research into nonalcoholic steatohepatitis (NASH), now more commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), though its strategic focus has broadened following changes in the competitive and clinical landscape.

The company’s principal revenue drivers have included research collaborations, licensing arrangements, milestone payments, and activities tied to its therapeutic development pipeline. Genfit has also developed diagnostic capabilities through its NIS4 technology platform intended to assist in identifying at-risk liver disease patients. Founded in 1999 and headquartered in Lille, France, Genfit evolved from a metabolic disease research company into a liver disease-focused biotechnology platform with international clinical development operations and partnerships across Europe and North America.

Business Operations

Genfit’s operations center on drug discovery, clinical-stage therapeutic development, and biomarker-based diagnostics. Its core pipeline includes programs targeting liver disease complications and oncology-related indications associated with hepatic dysfunction. The company’s lead therapeutic asset has included VS-01, a synthetic lipoprotein platform under development for acute-on-chronic liver failure, while oncology-oriented activities have involved treatments for cholangiocarcinoma and related conditions. Genfit also maintains diagnostic operations tied to its NIS4 biomarker technology, which has been evaluated for identifying patients with at-risk MASH.

The company conducts operations through research and development activities in Europe and maintains a broader international clinical and commercial orientation through partnerships and collaborations. Genfit has collaborated with larger pharmaceutical and healthcare entities for development, commercialization, and licensing purposes. Its historical partnership with Ipsen represented a significant strategic collaboration related to elafibranor, though development priorities shifted after late-stage clinical outcomes in NASH/MASH. Genfit’s assets include intellectual property portfolios covering therapeutic compounds, biomarker technologies, and liver disease-related diagnostic approaches.

Strategic Position & Investments

Genfit’s strategic direction has increasingly emphasized differentiated liver disease therapies, precision diagnostics, and high unmet-need indications where competition is comparatively narrower than the broader metabolic disease market. Following the discontinuation of key late-stage NASH ambitions tied to elafibranor, the company reoriented capital allocation toward acute liver disease management, rare disease opportunities, and biomarker-driven diagnostic tools. This repositioning has been reflected in investments into ACLF-focused programs and partnerships designed to extend the clinical and commercial applicability of its liver disease expertise.

The company has also expanded through acquisitions and portfolio investments aimed at strengthening its diagnostics and translational medicine capabilities. Genfit acquired Versantis AG, adding the VS-01 program and related ammonia-scavenging technologies to its portfolio. Its strategic focus includes integrating therapeutics and diagnostics in hepatology while leveraging clinical expertise in liver disease trial design and patient stratification. Genfit continues to participate in emerging sectors involving precision medicine, biomarker-enabled drug development, and advanced hepatology therapeutics.

Geographic Footprint

Genfit is headquartered in Lille, France, and maintains operational and clinical activities across multiple regions, particularly in Europe and North America. The company has historically engaged with regulatory agencies, clinical trial sites, and commercial partners in the United States, where much of the global biotechnology investment and liver disease drug development ecosystem is concentrated. Its shares have been traded on Euronext Paris, and the company has also maintained access to U.S. investors through American depositary or over-the-counter market structures.

The company’s clinical development programs have involved multinational trial participation across Europe, North America, and selected international markets. Genfit’s influence is strongest in the hepatology research community, where it has participated in global liver disease conferences, scientific collaborations, and international regulatory engagement. While the company does not operate as a large-scale commercial pharmaceutical enterprise, it maintains an international footprint through development partnerships, licensing arrangements, and cross-border clinical programs.

Leadership & Governance

Genfit was co-founded by Jean-François Mouney, who played a central role in shaping the company’s liver disease strategy and early public market development. The company’s governance model reflects a biotechnology-focused structure emphasizing scientific development, clinical execution, and strategic partnerships. Leadership has consistently highlighted precision medicine, innovation in hepatology, and disciplined portfolio management as central components of Genfit’s long-term strategy.

Key executives and leadership figures include:

• Pascal Prigent – Chief Executive Officer
• Jean-François Mouney – Co-Founder and former executive leadership figure
• Loïc Maurel – Chief Financial Officer
• Rémy Hanf – Chief Medical Officer
• Sophie Mégnien – Senior clinical and medical leadership roles associated with development operations

Company leadership has emphasized maintaining financial flexibility while advancing targeted liver disease assets with differentiated scientific profiles. Public disclosures, including SEC filings and European market reporting documents, indicate continued focus on strategic partnerships, clinical prioritization, and disciplined capital deployment.